These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18690954)

  • 21. Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals.
    Joosub I; Emara Z; Gray A
    Eur J Hosp Pharm; 2021 Sep; 28(5):280-283. PubMed ID: 34426482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of miniaturized near-infrared spectroscopy for quality control of extemporaneous orodispersible films.
    Foo WC; Widjaja E; Khong YM; Gokhale R; Chan SY
    J Pharm Biomed Anal; 2018 Feb; 150():191-198. PubMed ID: 29247960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extemporaneously compounded sterile medications: relevance of new United States pharmacopeial standards to pain clinicians.
    Rusho WJ
    J Pain Palliat Care Pharmacother; 2004; 18(4):69-76. PubMed ID: 15760810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.
    Neubert A; Dormann H; Weiss J; Egger T; Criegee-Rieck M; Rascher W; Brune K; Hinz B
    Drug Saf; 2004; 27(13):1059-67. PubMed ID: 15471510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations.
    Kiselova O; Maurina B; Sidlovska V
    Int J Pharm Compd; 2020; 24(6):491-500. PubMed ID: 33217739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
    Ghulam A; Keen K; Tuleu C; Wong IC; Long PF
    Ann Pharmacother; 2007 May; 41(5):857-60. PubMed ID: 17440007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature.
    Cuzzolin L; Zaccaron A; Fanos V
    Fundam Clin Pharmacol; 2003 Feb; 17(1):125-31. PubMed ID: 12588640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organization Expert Committee
    World Health Organ Tech Rep Ser; 2010; (957):1-276, back cover. PubMed ID: 20560300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patents and the quality, safety and efficacy of medicines.
    du Toit K; du Preez W; Padayachee S
    S Afr Med J; 2015 Nov; 105(11):905-6. PubMed ID: 26632315
    [No Abstract]   [Full Text] [Related]  

  • 32. Unlicensed and off-label drug use in children: implications for safety.
    Choonara I
    Expert Opin Drug Saf; 2004 Mar; 3(2):81-3. PubMed ID: 15006712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies.
    Buurma H; de Smet PA; van den Hoff OP; Sysling H; Storimans M; Egberts AC
    Pharm World Sci; 2003 Dec; 25(6):280-7. PubMed ID: 14689817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-label and unlicensed medicines to hospitalised children in Norway.
    Teigen A; Wang S; Truong BT; Bjerknes K
    J Pharm Pharmacol; 2017 Apr; 69(4):432-438. PubMed ID: 27334565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?
    Abraham J; Reed T
    Soc Sci Med; 2003 Jul; 57(2):195-204. PubMed ID: 12765701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unlicensed and off-label prescription of respiratory drugs to children.
    't Jong GW; Eland IA; Sturkenboom MC; van den Anker JN; Strickerf BH
    Eur Respir J; 2004 Feb; 23(2):310-3. PubMed ID: 14979509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.
    Turner S; Nunn AJ; Fielding K; Choonara I
    Acta Paediatr; 1999 Sep; 88(9):965-8. PubMed ID: 10519338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2011; (961):1-428, back cover. PubMed ID: 21699061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.